NCT05902962已完成1 期
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
PYC Therapeutics11 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2023年4月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 11
- 主要终点
- The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye
研究概览
简要总结
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female sex; ≥ 18 years of age at Baseline (Visit 2).
- •Have a molecular (genetic) diagnosis of PRPF31 mutation.
- •Have a clinical diagnosis of PRPF31 mutation-associated retinal dystrophy, that is, RP
- •The following conditions are allowed for inclusion if due to RP11, if in the opinion of the investigator they will not interfere with study evaluations or have resolved: macular edema (intraretinal, sub-retinal or other fluid) requiring regular treatment at a frequency of less than every 6 weeks; macular edema must be stable for at least 3 months prior to Screening (Visit 1). The investigator must consult with the study Medical Monitor.
- •If ≥ 18 years of age, understand the language of the informed consent and are willing and able to provide written informed consent prior to any study procedures. Are willing to comply with the instructions and attend all scheduled study visits.
- •6. Have light perception (LP) or better vision in the study eye.
- •Participants of childbearing potential and male participants must not be pregnant or lactating and must be sexually inactive by abstinence, which is consistent with the preferred and usual lifestyle of the participant or agree to use adequate birth control throughout study duration. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For nonsexually active participants, abstinence may be regarded as an adequate method of birth control. Participants of childbearing potential include all participants who have experienced menarche and have not undergone successful surgical sterilization (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) or are not post-menopausal (12 months after last menses).
排除标准
- •Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study that include but are not limited to infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues, or any other medical condition that may put the participant at risk due to study procedures.
- •Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PRPF31 mutations.
- •Have used anti-vascular endothelial growth factor (VEGF) agents within 2 months or corticosteroid injections within the last 3 months.
- •Have had Ozurdex® implants placed within 3 months or Retisert® or Iluvien® implants placed within 3 years prior to Baseline (Visit 2).
- •Within 3 months prior to Baseline (Visit 2), have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries [2 or more]) or any other ocular surgery.
- •Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmic evaluation or photography, as assessed by the investigator.
- •Have used any investigational drug or device within 90 days or 5 estimated half-lives of Baseline (Visit 2), whichever is longer, or plan to participate in another study of drug or device during the study period. Participation in observational trials is allowable based on investigator discretion and consultation with the Medical Monitor. It is assumed that the observational trial evaluations would not interfere with participation in this study.
- •Have received any prior cell or gene therapy for a retinal condition.
- •Have a recent history (<6 months) or current excessive recreational drug or alcohol use, in the opinion of the investigator.
- •Any retinal pathology other than RP11 that in the investigator's opinion could affect study results.
- •Participants should not have any conditions, in the investigator's opinion, that may put the participant at increased risk, confound study data, or interfere significantly with the participant's study participation.
研究组 & 干预措施
Single arm dose escalation study of VP-001
Experimental
干预措施: VP-001 (Drug)
结局指标
主要结局
The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye
时间窗: over a 48-week time period
The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye
时间窗: over a 24-week time period
次要结局
- Adverse Events and Treatment Emergent serious adverse events (SAEs) in the fellow eye(over a 48-week time period)
- Incidence, severity relatedness and of non-ocular TEAEs(over a 48-week time period)
- Adverse Events and Treatment Emergent Serious adverse events (SAEs) in the fellow eye(over a 24-week time period)
- Incidence, severity relatedness and of non-ocular TEAEs(over a 24-week time period)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)Retinitis Pigmentosa 11Eye DiseasesRetinal DiseaseRetinal DystrophiesRetinal DegenerationNCT06455826PYC Therapeutics6
已完成
1 期
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid TumorsSolid TumorNCT05176509Eucure (Beijing) Biopharma Co., Ltd5
终止
不适用
CivaSheet With Radical Prostatectomy & Adjuvant External Beam RadiationProstate CancerNCT03657108Icahn School of Medicine at Mount Sinai6
Enrolling By Invitation
1 期
A Clinical Study to Evaluate CUD005 Injection in Patients with Liver CirrhosisCirrhosis LiverNCT06671275Anhui Provincial Hospital9
已完成
1 期
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsAdvanced CancerMetastatic CancerNeoplasmsNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesNCT03510104Meryx, Inc.42